NeuroSense Therapeutics Ltd. NRSN
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) is a CNS/neurology/psychiatry drug developer. Its lead program, PrimeC (extended-release ciprofloxacin + celecoxib), is in Phase 2 for Amyotrophic lateral sclerosis (ALS). Its next catalyst on record is PrimeC: NeuroSense updates New Drug Submission (NDS) filing to Health Canada for PrimeC from December 2026 to March 2027 to incorporate new neurofilament light chain (NfL) data. (March 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PrimeC — NeuroSense updates New Drug Submission (NDS) filing to Health Canada for PrimeC from December 2026 to March 2027 to incorporate new neurofilament light chain (NfL) data. (March 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PrimeC | ALS (Phase 2b PARADIGM completed incl. 12-month open-label extension) | small molecule | Phase 2 |
| Ciprofloxacin/celecoxib combination | Alzheimer's disease (patent granted; no clinical trial described in extract) | small molecule | Pre-clinical |
Recent results and decisions
- Nov 2, 2026positive New neurofilament light chain (NfL) analysis from Phase 2b PARADIGM trial showed PrimeC-treated participants demonstrated greater reduction in NfL compared to placebo, with more pronounced effect in participants with higher baseline functionality.
In the new analysis, PrimeC-treated participants demonstrated a greater reduction in NfL compared to placebo, with an even more pronounced effect observed in participants with higher baseline functionality.
Filing - Nov 2, 2026n/a NeuroSense delays PrimeC Canadian NDS submission to March 2027 to include new neurofilament light chain (NfL) analysis.
The March 2027 filing target updates the previously announced December 2026 timetable, allowing the additional data to be included.
Filing - Jun 29, 2026met Phase 2b PARADIGM met primary efficacy endpoint: statistically significant TDP-43 reduction vs placebo at Day 180 (p=0.0421), sustained at Day 540 (p<0.001).
At Day 180, the pre-specified primary endpoint timepoint, PrimeC produced a statistically significant reduction in TDP-43 versus placebo (p=0.0421).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.